Equitec Proprietary Markets’s Lifecore Biomedical LFCR Stock Holding History

Equitec Proprietary Markets’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.9K	Buy	+5,000	New	+$23.2K	0.01%	55

Other funds holding LFCR

DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

CWC Advisors Lake Oswego, Oregon $215M AUM 18.92% 1-Year Est. Return

MAA

Mraz Amerine & Associates Modesto, California $640M AUM 12.53% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Equitec Proprietary Markets's LFCR Position: Q3 2026 in Review

Equitec Proprietary Markets opened a new position in Lifecore Biomedical (LFCR) in Q3 2026: 5,000 shares worth $32.9K. The stake represents 0.01% of the portfolio and ranks #55 among its holdings.

24 funds tracked by Wall St. Rank hold LFCR as of Q3 2026.

Equitec Proprietary Markets held 5,000 shares of Lifecore Biomedical worth $32.9K as of Q3 2026.
Lifecore Biomedical was a new Equitec Proprietary Markets position in Q3 2026.
Lifecore Biomedical made up 0.01% of Equitec Proprietary Markets's portfolio in Q3 2026, its #55 holding.
24 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2026.

Based on Equitec Proprietary Markets's 13F filing for Q3 2026, filed 4 Nov 2026.